New York, June 9, 2022 – Tiziana Life Sciences Ltd.(Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery.
In the Second Patient with Secondary Progressive Multiple Sclerosis (SPMS) Following Three Months of Dosing with Intranasal Foralumab.
Redx Announces Collaboration with the Garvan Institute of Medical Research
Covering OKYO’s dry eye drug candidate OK-101 for use to treat ocular neuropathic pain.
OKYO to File IND in Q3 2022 for OK-101 to treat Dry Eye Disease (“DED”) and to go directly to a Phase 2 Human Clinical Efficacy Trial in DED Patients
Major US hospital-based clinical trial highlights benefit of nasal decolonization to reduce ICU infections caused by Staphylococcus aureus
On September 2nd, Tiziana Life Sciences PLC (NASDAQ:TLSA) (LSE:TILS) announced an exclusive licensing agreement with Precision BioSciences (NASDAQ:DTIL) for the exploration and development of foralumab as a lymphodepletion agent to
Tiziana to Host Investor Call to Discuss Exclusive License Agreement to Evaluate Foralumab, a Novel, Fully Human Anti-CD3 Monoclonal Antibody, in Conjunction with Allogeneic CAR T Candidates for Cancer Treatment
London/New York, 3 September 2021 – Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS) (“Old Tiziana”) a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases
Precision BioSciences and Tiziana Life Sciences Announce Exclusive License Agreement to Evaluate Foralumab, a Novel, Fully Human Anti-CD3 Monoclonal Antibody, in Conjunction with Allogeneic CAR T Candidates for Cancer Treatment
London/New York, August 20, 2021 – Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS) (“Old Tiziana”) a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases
